Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 351, Issue -, Pages 66-70Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2021.12.050
Keywords
SGLT-2 inhibitors; Heart failure; Type 2 diabetes; Management; Multidisciplinary
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were initially approved for diabetes treatment, but now they are being recognized as promising agents for treating heart failure and chronic kidney disease, even in non-diabetic patients. However, the use of these drugs in frail patients with multiple pathologies can be complex and require a multidisciplinary approach.
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i), initially studied and approved for the treatment of diabetes, are now becoming a promising class of agents to treat heart failure (HF) and chronic kidney disease (CKD), even in patients without diabetes. While the potential benefits in several diseases (usually treated by different medical specialties) is amplifying the interest in these drugs, their use in frail patients with multiple pathologies and on polypharmacy can be complex, requiring a composite multidisciplinary approach. Following a brief overview of the evidence supporting the benefits of SGLT-2i in patients with HF or CKD, we herein provide guidance for prescribing SGLT-2i in daily practice using a multidisciplinary approach. A shared treatment algorithm is presented for initiating an SGLT-2i in patients already being treated for diabetes and HF. Tools to prevent hypoglycemia, blood pressure drop, genital infections, euglycemic diabetic ketoacidosis and eGFR dip are also provided. It is hoped that this practical, multidisciplinary guidance for initiating SGLT-2i in patients with HF and/or CKD, whatever therapy they are currently on, can help to offer SGLT-2i to the largest population of patients possible to provide the most therapeutic benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available